Pathology Doctors in Dover, NH Accepting Medicare

4 Pathology doctors found. Showing 1 - 4

David A Novis, M.D. Pathology - Clinical Pathology/Laboratory Medicine Medicare: Not Enrolled in Medicare Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-742-2132

Glenn Harold Littell, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-742-2132

Dr. Polius Raslavicius, M.D. Pathology - Anatomic Pathology & Clinical Pathology Medicare: Not Enrolled in Medicare Practice Location: 789 Central Ave, Wentworth-douglass Hospital, Dover, NH 03820 Phone: 603-335-2338

Dr. Lucy Harn Kapur, MD Pathology - Hematology Medicare: Accepting Medicare Assignments Practice Location: 789 Central Ave, Dover, NH 03820 Phone: 603-742-5252

News Archive

Study: Tooth decay may have detrimental effect on child's quality of life and success in life

Dental caries, commonly known as tooth decay, is the single most common chronic childhood disease. In fact, it is an infectious disease. Mothers with cavities can transmit caries-producing oral bacteria to their babies when they clean pacifiers by sticking them in their own mouths or by sharing spoons.

Researchers develop new computation method for better estimation of indoor carbon dioxide

The air we breathe out can help us improve the quality of the air we breathe in. Measurements of indoor carbon dioxide (CO2) concentrations are used to evaluate indoor air quality, which is strongly linked to the levels of contaminants, such as gases and particles, circulating about with CO2.

Report: FDA conflict-of-interest rules too restrictive

The conflict-of-interest policies in the medical profession are coming under fire as too stringent and as impeding medical progress, a claim the Food and Drug Administration dismisses as a misunderstanding of its rules.

Molina Healthcare prices common stock public offering at $27.00 per share

Molina Healthcare, Inc. announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of common stock by the Company at a public offering price of $27.00 per share. The Company intends to use the net proceeds from the offering to reduce its borrowings under its $200 million senior secured credit facility, which credit facility had an outstanding balance of $105.0 million as of July 30, 2010.

Epiphany Biosciences announces results from its valomaciclovir Phase 2b trial for shingles

Epiphany Biosciences announced results from its Phase 2b dose-ranging study of EPB-348 (valomaciclovir) in patients with shingles (herpes zoster) infection. The study's primary endpoint was non-inferiority of once-daily valomaciclovir compared to thrice-daily valacyclovir in terms of time to complete crusting of the shingles rash.

Read more Medical News

› Verified 2 days ago